Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546362 | 0.85 | P2RX3 (0.36) | P2RX3P2RX2MCOLN2CYP11B1CYP11B2 | |
| SCHEMBL21347897 | 0.83 | MCOLN2 (0.36) | MCOLN2CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL26558669 | 0.79 | P2RX3 (0.34) | P2RX3P2RX2 | |
| SCHEMBL21041367 | 0.76 | P2RX3 (0.33) | P2RX3P2RX2CYP11B1CYP11B2 | |
| SCHEMBL25484605 | 0.74 | CYP11B1 (0.33) | P2RX3P2RX2MCOLN2CYP11B1CYP11B2 | |
| SCHEMBL25618878 | 0.74 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL26315298 | 0.72 | HDAC4 (0.31) | — | |
| SCHEMBL31214086 | 0.71 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL2737342 | 0.71 | P2RX3 (0.33) | P2RX3P2RX2 | |
| SCHEMBL21340203 | 0.71 | MCOLN2 (0.33) | MCOLN2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | P2RX3 4854/4885P2RX2 4810/4885MCOLN2 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.